Fund news

Amsterdam, The Netherlands – January 23, 2020: iOnctura B.V., a clinical stage biopharmaceutical company, developing a pipeline of next generation molecules targeting cancer and fibrosis, announces today the closing of a EUR 15 million Series A financing. The financing was led by INKEF Capital and co-led by VI Partners with participation by new investors Schroder Read the full article…

Zurich, Switzerland – August 20, 2019: Araris Biotech AG announced today the closing of an oversubscribed seed financing round of CHF 2.5 million with participation of Swiss investors Redalpine, Schroder Adveq and VI Partners. The proceeds will be used to develop a pipeline of proprietary antibody-drug conjugates (ADCs). Araris’ co-founder and Chief Executive Officer, Dr. Read the full article…

Morges, Switzerland – July 23, 2019: Gamaya, active in precision agriculture, raised 12 million francs in a series B financing round, including 4.2 million francs in the form of convertible bonds in what marks a turning point for this EPFL spin-off. Gamaya’s story begins in an academic laboratory in Lausanne and continues on large agricultural Read the full article…

L.E.S.S. SA, a high tech company manufacturing a new generation of ultra-bright and ultra-thin lighting systems, announced today the closing of a CHF 14 million Series B financing round to accelerate the industrialization of their products in the automotive market. The round was led by new private and existing investors. L.E.S.S. SA was founded in Read the full article…

Altoida Inc. today announced a $6.3 million round of venture capital financing to bring its FDA-cleared and CE Mark-approved medical device and brain health data platform to patients, physicians and researchers around the globe. Led by a team of esteemed neuroscientists, physicians and computer scientists, Altoida uses digital biomarkers to drive better clinical outcomes for Read the full article…

Sequana Medical NV – (“Sequana Medical”, the “Company”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces the results of its initial public offering of new shares, with the admission of all of Read the full article…

Kuros Biosciences (SIX: KURN) (the Company or Kuros) announces the final number of offered shares and gross proceeds from the rights offering and share placement, first announced on November 29, 2018, in which a total of 8,013,306 new registered shares of Kuros sourced from the ordinary and authorized share capital with a nominal value of CHF 1.00 Read the full article…

Nexthink®, the leader in digital employee experience management software for enterprises, today announced it has secured an $85 million funding round. The financing was led by Index Ventures and includes participation from returning investors Highland Europe, Forestay Capital, VI Partners, Auriga Partners and Galéo Capital and new investors TOP Funds and Olivier Pomel, Co-founder and CEO of Datadog. Over the past few years, Nexthink has Read the full article…

Ledgy AG, Zurich (Switzerland), provider of equity software for private companies, has collected 1 million euros in a successful seed round. The company secured funding from a strong alliance of European investors: In addition to btov Partners (St. Gallen, Switzerland), Creathor Ventures (Bad Homburg, Germany) and VI Partners (Zug, Switzerland) are involved. Daniel Gutenberg and Read the full article…

AMAL Therapeutics (AMAL), the Swiss biotech developing novel, peptide-based therapeutic cancer vaccines, today announces that it has completed the second closing of its Series B financing round. The second and final tranche of €21.2 million (CHF 24.2 million) brings the total round to just over €29 million (CHF 33.2 million). The Company will use the Read the full article…

Equippo, an online marketplace for construction equipment, has acquired a Berlin-based startup and simultaneously expanded its services with a permanent auction yard in Belgium. These strategic moves come after Equippo closed a new financing round from existing investors. Equippo’s online platform, allows customers to purchase used heavy equipment from the US and Europe selling as high as 500,000 US dollars. Read the full article…

Sequana Medical NV (“Sequana Medical” , the “Company” ), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today the opening of its new corporate headquarters in Ghent, Belgium, at the epicentre of the Flanders healthcare hub, and Read the full article…

CeQur® today announced that the Journal of Health Economics and Outcomes Research (JHEOR) published online an analysis evaluating the cost effectiveness of the company’s PAQ® Insulin Delivery Device. The analysis suggests that the simple three-day, wearable PAQ basal-bolus insulin delivery device is more cost-effective than multiple daily insulin injections (MDI) and results in a lifetime cost savings of more Read the full article…

Kuros Biosciences (SIX: KURN) today announced that the first patient has been treated in an investigator-led multicenter randomized controlled study comparing MagnetOs with autologous bone in posterolateral spinal fusion. The University Medical Center Utrecht (UMCU) in the Netherlands is the principal investigating site for the study, which is entitled “A Randomized Controlled Trial of MagnetOs® Read the full article…

Sequana Medical AG (“Sequana Medical”), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today positive findings from its Retrospective Malignant Ascites Study. The study retrospectively evaluated 17 patients with malignant ascites that had been implanted with Read the full article…

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today that the independent Safety Monitoring Board (SMB) for its Phase 2 trial of GKT831 for the treatment of Primary Biliary Cholangitis (PBC) held its second pre-planned data review meeting and recommended the continuation of the Company’s Read the full article…

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today that 90 patients have been randomized in its Phase 2 trial of GKT831 for the treatment of Primary Biliary Cholangitis (PBC). This represents the target number of patients required to conduct the pre-planned interim analysis. The Read the full article…

JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced initiation of patient enrollment in the Early Feasibility Study (EFS) of its next generation JenaValve Pericardial TAVR System using the Everdur™ transcatheter heart valve (THV) and CoronatixTM Transfemoral Delivery Catheter at NewYork-Presbyterian/ Columbia University Medical Center (CUMC), New York City, and MedStar Washington Hospital Center, Read the full article…

Sennheiser is aiming to strengthen its position as a leading provider of immersive audio solutions with an investment in Dear Reality, experts in spatial audio algorithms and audio VR/AR software, and the acquisition of technologies from Sonic Emotion, a developer of 3D audio software and processing solutions. Both companies have developed unique expertise and tools for Read the full article…

Suunto, a global leader in sports precision instruments and Myotest, a global leader in advanced, accelerometer-based analysis and interpretation for digital sport, today announced technology collaboration for a new running solution. Suunto has a long heritage in building robust sports watches known for their precision and sports expertise targeted to performance oriented athletes, while Myotest’s personalized smart Read the full article…

Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a biotechnology company developinginnovative immunotherapies, and Genkyotex, a Swiss privately-held biopharmaceutical company and the leader in NOX therapies, announced today that Genticel has signed a contribution agreement with the shareholders of Genkyotex pursuant to which, subject to the approval of Genticel’s shareholders at a meeting expected to be held in Read the full article…

Inositec, a pioneer in the development of life-saving small molecule drugs based on inositol hexaphosphate (IP6), announced today the closing of a CHF1.4 million (US$1.42 million) seed financing. Investors participating in the round included VI Partners via the Venture Incubator fund and Zürcher Kantonalbank. The proceeds will be used to progress a drug candidate from Read the full article…

Cell Medica, a leader in developing, marketing and manufacturing cellular therapeutics for cancer and viral infections, announced today the acquisition of Delenex Therapeutics AG, a privately held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. The acquisition will enable Cell Medica to accelerate the development of gene-modified immune Read the full article…

Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners and High-Tech Gründerfonds also participated in the round which will help progress Amal’s cancer vaccines. Amal Therapeutics is a Swiss biotech company developing and progressing therapeutic cancer vaccines. The company Read the full article…

If you follow the Equippo blog, you’ll remember that Equippo announced its first financing round with b-to-v partners in June, 2015. Fast forward half a year, and we’re happy to announce the closing of our second major funding round with Swiss firm VI Partners. After celebrating Equippo’s first birthday on November 17th, this financing round comes at a Read the full article…

Cytos Biotechnology Ltd. (SIX:CYTN) (“Cytos”) and Kuros Biosurgery Holding AG (“Kuros”), today announced their intention to combine their businesses by way of an exchange of Kuros shares for new Cytos shares, subject to shareholder approval and other customary conditions. Cytos is listed on the main segment of the Swiss stock exchange (SIX Swiss Exchange) while Read the full article…

Mit Swisscom Friends bietet Swisscom ihren Kunden gemeinsam mit dem Startup Mila seit zwei Jahren einen zusätzlichen, flexiblen und raschen Vor-Ort-Kundensupport. Swisscom hat nun die Mehrheit am Startup Mila übernommen. Mit der Investition baut der Schweizer ICT-Anbieter seine Aktivitäten im Bereich Shared Economy weiter aus. Mit Swisscom Friends erhalten Kunden auf einfache Weise kompetente und Read the full article…

Vectura Group plc (LSE: VEC; “Vectura” or the “Company”) announces the acquisition of Activaero GmbH (“Activaero”) for a total consideration of €130 million (£108 million) to be funded through a combination of existing cash and equity. Activaero is a private German pharmaceutical company focused on the development of products for the treatment of respiratory diseases. Its proprietary smart Read the full article…

St. Jude Medical, Inc. (NYSE: STJ), a global medical device company, today announced the acquisition of Endosense SA, a Switzerland-based company that has pioneered contact-force measurement in catheter ablation. The acquisition adds to the company’s leading electrophysiology portfolio and provides a robust platform for future product development. St. Jude Medical has made an initial payment of approximately 159 Read the full article…

Merz Pharma Group (Frankfurt am Main) today announced that it has acquired the Swiss pharmaceutical company Neocutis S.A. The acquisition of the company`s cosmeceutical skin care business strengthens Merz`s market position in the field of aesthetic dermatology. “Neocutis is an innovative company with an excellent presence on the U.S. market, and a promising potential for development,” said Philip Burchard, CEO of Read the full article…